Ost-müük Black Diamond Therapeutics, Inc. - BDTX CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.0672 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Black Diamond Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Eelmine sulgemine* | 2.3266 |
Avatud* | 2.3465 |
Aastane muutus* | 33.32% |
Päeva ulatus* | 2.3465 - 2.4963 |
52 nädala ulatus | 1.18-4.08 |
Keskmine maht (10 päeva) | 74.14K |
Keskmine maht (3 kuud) | 1.74M |
Turukapitalisatsioon | 85.44M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 36.51M |
Tulu | N/A |
EPS | -2.38 |
Dividendid (% kasumist) | N/A |
Beeta | 1.89 |
Järgmine tuluaruande kuupäev | Aug 7, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Jun 5, 2023 | 2.4564 | 0.1998 | 8.85% | 2.2566 | 2.5063 | 2.2366 |
Jun 2, 2023 | 2.3266 | 0.1399 | 6.40% | 2.1867 | 2.3665 | 2.0969 |
Jun 1, 2023 | 2.1368 | 0.3295 | 18.23% | 1.8073 | 2.1668 | 1.7973 |
May 31, 2023 | 1.8373 | 0.0300 | 1.66% | 1.8073 | 1.8572 | 1.7973 |
May 30, 2023 | 1.8572 | 0.0999 | 5.68% | 1.7573 | 1.8772 | 1.7573 |
May 26, 2023 | 1.7673 | 0.0699 | 4.12% | 1.6974 | 1.7774 | 1.6575 |
May 25, 2023 | 1.7274 | 0.0699 | 4.22% | 1.6575 | 1.7574 | 1.6575 |
May 24, 2023 | 1.6974 | 0.0100 | 0.59% | 1.6874 | 1.7374 | 1.6375 |
May 23, 2023 | 1.6775 | -0.1298 | -7.18% | 1.8073 | 1.8672 | 1.6774 |
May 22, 2023 | 1.8373 | 0.0899 | 5.14% | 1.7474 | 1.8772 | 1.7474 |
May 19, 2023 | 1.7773 | 0.0699 | 4.09% | 1.7074 | 1.7873 | 1.6175 |
May 18, 2023 | 1.5976 | -0.0998 | -5.88% | 1.6974 | 1.6975 | 1.5576 |
May 17, 2023 | 1.7074 | -0.0400 | -2.29% | 1.7474 | 1.7674 | 1.6774 |
May 16, 2023 | 1.7673 | -0.1198 | -6.35% | 1.8871 | 1.9171 | 1.7673 |
May 15, 2023 | 1.9171 | 0.1198 | 6.67% | 1.7973 | 1.9271 | 1.7573 |
May 12, 2023 | 1.8672 | -0.0399 | -2.09% | 1.9071 | 1.9071 | 1.8073 |
May 11, 2023 | 1.9171 | 0.1098 | 6.08% | 1.8073 | 1.9970 | 1.7973 |
May 10, 2023 | 1.8472 | 0.0499 | 2.78% | 1.7973 | 1.8972 | 1.7973 |
May 9, 2023 | 1.8173 | 0.0400 | 2.25% | 1.7773 | 1.8173 | 1.6575 |
May 8, 2023 | 1.9072 | 0.0300 | 1.60% | 1.8772 | 1.9371 | 1.8572 |
Black Diamond Therapeutics, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Friday, June 9, 2023 | ||
Kellaaeg (UTC) (UTC) 16:45 | Riik US
| Sündmus Black Diamond Therapeutics Inc at Jefferies Healthcare Conference Black Diamond Therapeutics Inc at Jefferies Healthcare ConferenceForecast -Previous - |
Monday, August 7, 2023 | ||
Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q2 2023 Black Diamond Therapeutics Inc Earnings Release Q2 2023 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
Kellaaeg (UTC) (UTC) 13:30 | Riik US
| Sündmus Q3 2023 Black Diamond Therapeutics Inc Earnings Release Q3 2023 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 92.828 | 126.872 | 69.57 | 29.332 | 8.904 |
Müük/Üldine/admin kulud, kokku | 28.391 | 30.043 | 21.361 | 7.579 | 1.954 |
Uuringud ja arendus | 64.437 | 96.829 | 48.209 | 21.753 | 6.95 |
Ootamatud kulutused (tulu) | 0 | ||||
Tulud majandustegevusest | -92.828 | -126.872 | -69.57 | -29.332 | -8.904 |
Intressitulud (kulu), muud tulud, neto | -0.219 | 3.464 | 4.041 | -5.932 | -0.011 |
Muud, neto | -0.354 | -2.188 | -1.725 | 0.006 | -0.016 |
Netotulu enne makse | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Netotulu pärast makse | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Netotulu enne erikulusid | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Netotulu | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Arvestatav tulu, v a erikulud | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Arvestatav tulu, koos erikuludega | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Jaotamisele kuuluv netotulu | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Keskmine jaotamisele kuuluv aktsia kohta | 36.3256 | 36.189 | 32.9071 | 32.6364 | 32.6364 |
Jaotatav EPS, v a erakorralised kulud | -2.50977 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Jaotamisele kuuluv normaal-EPS | -2.57122 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
Gain (Loss) on Sale of Assets | 2.232 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 21.561 | 21.852 | 22.124 | 23.173 | 25.679 |
Müük/Üldine/admin kulud, kokku | 6.808 | 7.243 | 6.277 | 6.978 | 7.893 |
Uuringud ja arendus | 14.753 | 14.609 | 15.847 | 16.195 | 17.786 |
Tulud majandustegevusest | -21.561 | -21.852 | -22.124 | -23.173 | -25.679 |
Intressitulud (kulu), muud tulud, neto | 0.622 | -1.573 | 0.562 | 0.386 | 0.406 |
Muud, neto | 0.064 | 0.115 | -0.092 | -0.143 | -0.234 |
Netotulu enne makse | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
Netotulu pärast makse | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
Netotulu enne erikulusid | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
Netotulu | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
Arvestatav tulu, v a erikulud | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
Arvestatav tulu, koos erikuludega | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
Jaotamisele kuuluv netotulu | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
Keskmine jaotamisele kuuluv aktsia kohta | 36.4839 | 36.3902 | 36.3462 | 36.2939 | 36.2713 |
Jaotatav EPS, v a erakorralised kulud | -0.57217 | -0.57922 | -0.59577 | -0.63179 | -0.70323 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.57217 | -0.64056 | -0.59577 | -0.63179 | -0.70323 |
Gain (Loss) on Sale of Assets | 2.232 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 127.706 | 215.703 | 319.554 | 155.714 | 51.684 |
Raha ja lühiajalised investeeringud | 122.807 | 209.786 | 315.067 | 154.666 | 51.66 |
Raha ja ekvivalendid | 34.315 | 65.799 | 34.605 | 154.666 | 51.66 |
Prepaid Expenses | 4.899 | 5.917 | 4.487 | 1.048 | 0.024 |
Total Assets | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
Property/Plant/Equipment, Total - Net | 27.381 | 30.74 | 8.787 | 0.164 | 0.134 |
Property/Plant/Equipment, Total - Gross | 28.131 | 31.109 | 8.951 | 0.276 | 0.234 |
Accumulated Depreciation, Total | -0.75 | -0.369 | -0.164 | -0.112 | -0.1 |
Other Long Term Assets, Total | 1.168 | 1.239 | 1.329 | 2.417 | 0.008 |
Total Current Liabilities | 15.261 | 23.642 | 14.218 | 4.863 | 2.575 |
Accounts Payable | 1.877 | 4.107 | 2.538 | 1.964 | 0.416 |
Accrued Expenses | 13.384 | 19.535 | 11.68 | 2.899 | 0.452 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 1.707 | |||
Total Liabilities | 40.56 | 51.782 | 21.912 | 4.879 | 6.598 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 25.299 | 28.14 | 7.694 | 0.016 | 4.023 |
Total Equity | 115.695 | 195.9 | 307.758 | 153.416 | 45.228 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 60.77 | ||
Common Stock | 0.005 | 0.005 | 0.005 | 0.001 | 0.001 |
Additional Paid-In Capital | 452.503 | 440.129 | 425.363 | 3.812 | 0.169 |
Retained Earnings (Accumulated Deficit) | -334.989 | -243.82 | -118.224 | -50.97 | -15.712 |
Total Liabilities & Shareholders’ Equity | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
Total Common Shares Outstanding | 36.4343 | 36.2346 | 36.0784 | 32.6364 | 32.6364 |
Redeemable Preferred Stock | 0 | 0 | 200.573 | ||
Lühiajalised investeeringud | 88.492 | 143.987 | 280.462 | ||
Other Equity, Total | -0.414 | 0.614 | |||
Unrealized Gain (Loss) | -1.824 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 107.977 | 127.706 | 150.978 | 168.558 | 188.304 |
Raha ja lühiajalised investeeringud | 103.366 | 122.807 | 144.181 | 160.89 | 179.739 |
Raha ja ekvivalendid | 39.141 | 34.315 | 53.96 | 55.877 | 54.081 |
Lühiajalised investeeringud | 64.225 | 88.492 | 90.221 | 105.013 | 125.658 |
Prepaid Expenses | 4.611 | 4.899 | 6.797 | 7.668 | 8.565 |
Total Assets | 135.582 | 156.255 | 180.416 | 198.834 | 219.482 |
Property/Plant/Equipment, Total - Net | 26.437 | 27.381 | 28.27 | 29.098 | 29.945 |
Property/Plant/Equipment, Total - Gross | 27.282 | 28.131 | 28.98 | 29.681 | 30.439 |
Accumulated Depreciation, Total | -0.845 | -0.75 | -0.71 | -0.583 | -0.494 |
Other Long Term Assets, Total | 1.168 | 1.168 | 1.168 | 1.178 | 1.233 |
Total Current Liabilities | 12.847 | 15.261 | 21.143 | 19.706 | 19.469 |
Accounts Payable | 3.046 | 1.877 | 5.76 | 2.222 | 1.883 |
Accrued Expenses | 9.801 | 13.384 | 15.383 | 17.484 | 17.586 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 37.392 | 40.56 | 47.185 | 46.463 | 46.922 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 24.545 | 25.299 | 26.042 | 26.757 | 27.453 |
Total Equity | 98.19 | 115.695 | 133.231 | 152.371 | 172.56 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 |
Additional Paid-In Capital | 455.225 | 452.503 | 449.625 | 446.909 | 443.657 |
Retained Earnings (Accumulated Deficit) | -355.864 | -334.989 | -313.911 | -292.257 | -269.327 |
Other Equity, Total | -1.176 | -1.824 | -2.488 | -2.286 | -1.775 |
Total Liabilities & Shareholders’ Equity | 135.582 | 156.255 | 180.416 | 198.834 | 219.482 |
Total Common Shares Outstanding | 36.512 | 36.4343 | 36.3662 | 36.3157 | 36.2876 |
Redeemable Preferred Stock |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Raha majandustegevusest | -85.082 | -100.148 | -52.146 | -24.674 | -8.454 |
Raha majandustegevusest | 0.508 | 0.205 | 0.052 | 0.047 | 0.044 |
Mittelikviidsed varad | 15.48 | 18.223 | 10.014 | 10.074 | 0.079 |
Muutused tööjõus | -9.901 | 7.02 | 5.042 | 0.463 | 0.354 |
Tulu investeeringutelt | 53.366 | 130.613 | -281.691 | -0.021 | -0.076 |
Kapitalikulutused | -0.192 | -2.71 | -0.142 | -0.021 | -0.076 |
Muud rahavood investeeringutelt, kokku | 53.558 | 133.323 | -281.549 | 0 | |
Rahavood investeeringutelt | 0.177 | 0.729 | 214.944 | 127.756 | 52.312 |
Rahavoogudesse investeerimine | 0 | -1.743 | 0 | ||
Aktsiate emiteerimine (tagasiost), neto | 0.177 | 0.729 | 214.944 | 129.499 | 52.312 |
Laenu väljastamine (kustutamine), neto | 0 | ||||
Rahaline kogumuutus | -31.539 | 31.194 | -118.893 | 103.061 | 43.782 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -20.875 | -91.169 | -70.091 | -48.437 | -25.507 |
Cash From Operating Activities | -20.031 | -85.082 | -63.143 | -46.667 | -28.6 |
Cash From Operating Activities | 0.122 | 0.508 | 0.382 | 0.253 | 0.125 |
Non-Cash Items | 3.507 | 15.48 | 11.804 | 8.366 | 4.293 |
Changes in Working Capital | -2.785 | -9.901 | -5.238 | -6.849 | -7.511 |
Cash From Investing Activities | 24.806 | 53.366 | 51.044 | 36.537 | 16.729 |
Capital Expenditures | 0 | -0.192 | -0.192 | -0.2 | -0.007 |
Other Investing Cash Flow Items, Total | 24.806 | 53.558 | 51.236 | 36.737 | 16.736 |
Cash From Financing Activities | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
Issuance (Retirement) of Stock, Net | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
Net Change in Cash | 4.826 | -31.539 | -11.894 | -9.977 | -11.718 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Versant Ventures | Venture Capital | 17.6634 | 6449348 | 0 | 2023-03-15 | LOW |
Bellevue Asset Management AG | Investment Advisor | 14.778 | 5395839 | -5000 | 2023-03-31 | LOW |
New Enterprise Associates (NEA) | Venture Capital | 9.4454 | 3448757 | 0 | 2023-03-31 | LOW |
RA Capital Management, LP | Hedge Fund | 7.0932 | 2589904 | 0 | 2023-03-31 | LOW |
Boxer Capital, L.L.C. | Hedge Fund | 5.5183 | 2014858 | 0 | 2023-03-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 4.5095 | 1646517 | 0 | 2023-03-31 | LOW |
EcoR1 Capital, LLC | Hedge Fund | 3.2621 | 1191094 | 908963 | 2023-03-31 | LOW |
Epstein (David M) | Individual Investor | 2.5703 | 938479 | 0 | 2023-03-15 | LOW |
Millennium Management LLC | Hedge Fund | 2.1269 | 776594 | 252037 | 2023-03-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0749 | 757585 | 0 | 2023-03-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.5276 | 557771 | -216027 | 2023-03-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4344 | 523719 | -127676 | 2023-03-31 | LOW |
Verition Fund Management LLC | Hedge Fund | 0.943 | 344307 | 344307 | 2023-03-31 | HIGH |
Newtyn Management, LLC | Hedge Fund | 0.8397 | 306609 | -8391 | 2023-03-31 | MED |
Two Sigma Investments, LP | Hedge Fund | 0.7769 | 283654 | -72510 | 2023-03-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7406 | 270428 | 5138 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.5957 | 217500 | -3113 | 2023-03-31 | HIGH |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.5023 | 183398 | -102283 | 2023-03-31 | LOW |
BioImpact Capital LLC | Investment Advisor/Hedge Fund | 0.3968 | 144888 | 0 | 2023-03-31 | LOW |
Tekla Capital Management LLC | Investment Advisor | 0.3615 | 131990 | 0 | 2023-03-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Black Diamond Therapeutics, Inc. Company profile
Ettevõttest Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. on täpse onkoloogilise meditsiini ettevõte. Ettevõte keskendub väikeste molekulide, MasterKey ravimeetodite avastamisele ja arendamisele. Ettevõte arendab väikesemolekulaarsete kinaasi inhibiitorite tooteprogrammi, mis on suunatud erinevatele vähktõve juhtmutatsioonidele. Ettevõtte tehnoloogiaplatvorm, Mutation-Allostery-Pharmakoloogia (MAP) platvorm on loodud selleks, et analüüsida populatsioonitasandi geneetilise sekveneerimise andmeid, et avastada onkogeensed mutatsioonid, mis soodustavad vähktõbe kõigis kasvajatüüpides. Ettevõtte juhtiv tootekandidaat BDTX-189 on loodud suukaudselt manustatava, pöördumatu väikese molekuli inhibiitorina, mis on suunatud 48 mitte-kanoonilise ja kanoonilise ErbB-kinaasi epidermise kasvufaktori retseptori (EGFR) ja HER2 juhtmutatsioone hõlmavale spektrile. BDTX-1535 on aju läbitav inhibiitor, mis on suunatud EGFR-i mutatsioonide spektrile, sealhulgas allosteerilistele ja kanoonilistele mutatsioonidele. Sellel on ka varajases staadiumis olevad programmid, nagu B-Raf proto-onkogeen (BRAF) ja fibroblastide kasvufaktori retseptor (FGFR).
Industry: | Bio Therapeutic Drugs |
One Main Street, 14th Floor
CAMBRIDGE
MASSACHUSETTS 02142
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com